Regeneron Pharmaceuticals, Inc.
corporate_fare Company Profile
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for REGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for REGN spans 8-K, 13F-HR, 10-Q.
Recent high-impact activity:
- FDA Approves Livsayis, First siRNA Therapy for Generalized Myasthenia Gravis
- Single-Dose CIDEB siRNA Cuts Liver Fat Up to 80% in MASLD, Published in NEJM
- Regeneron Hits 52-Week High as Q3 EPS Tops Consensus by 24%
- Regeneron Q3 Revenue Jumps 36% to $5.1B; Non-GAAP EPS Up 70% to $20.07, Guidance Raised
- Regeneron Posts $18.45 Q3 EPS as Shares Sit Near 52-Week High
Financial Snapshot
Short Interest & Short Volume
2.73 days to coverFINRA reported short interest of 2,217,114 shares in REGN as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 38.9% of REGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.